BR112017007089A2 - métodos melhorados para a inativação de enterovírus, adsorção de adjuvante e composições de vacina reduzidas por dose daí obtidas - Google Patents
métodos melhorados para a inativação de enterovírus, adsorção de adjuvante e composições de vacina reduzidas por dose daí obtidasInfo
- Publication number
- BR112017007089A2 BR112017007089A2 BR112017007089A BR112017007089A BR112017007089A2 BR 112017007089 A2 BR112017007089 A2 BR 112017007089A2 BR 112017007089 A BR112017007089 A BR 112017007089A BR 112017007089 A BR112017007089 A BR 112017007089A BR 112017007089 A2 BR112017007089 A2 BR 112017007089A2
- Authority
- BR
- Brazil
- Prior art keywords
- improved methods
- dose
- obtained therefrom
- vaccine compositions
- compositions obtained
- Prior art date
Links
- 241000709661 Enterovirus Species 0.000 title abstract 2
- 230000002779 inactivation Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000001179 sorption measurement Methods 0.000 title abstract 2
- 239000002671 adjuvant Substances 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 abstract 1
- 229960000281 trometamol Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/06—Inactivation or attenuation by chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32311—Enterovirus
- C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32661—Methods of inactivation or attenuation
- C12N2770/32663—Methods of inactivation or attenuation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32671—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente invenção é direcionada a métodos melhorados de inativação de enterovírus através de formaldeído na presença de tampão de trometamina que resulta em uma recuperação máxima do antígeno d. a subsequente adsorção de dita sipv em hidróxido de alumínio fornece composições de sipv de dose significativamente reduzidas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3180MU2014 | 2014-10-07 | ||
PCT/IN2015/000376 WO2016063291A1 (en) | 2014-10-07 | 2015-10-06 | Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017007089A2 true BR112017007089A2 (pt) | 2017-12-26 |
Family
ID=55300742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017007089A BR112017007089A2 (pt) | 2014-10-07 | 2015-10-06 | métodos melhorados para a inativação de enterovírus, adsorção de adjuvante e composições de vacina reduzidas por dose daí obtidas |
Country Status (24)
Country | Link |
---|---|
US (1) | US10485862B2 (pt) |
EP (2) | EP3204494B1 (pt) |
JP (2) | JP6755243B2 (pt) |
KR (2) | KR102219638B1 (pt) |
CN (2) | CN106999569B (pt) |
AU (2) | AU2015334495B2 (pt) |
BR (1) | BR112017007089A2 (pt) |
CA (1) | CA2963897C (pt) |
CU (1) | CU24510B1 (pt) |
CY (1) | CY1123078T1 (pt) |
DK (1) | DK3204494T3 (pt) |
EA (1) | EA201700187A1 (pt) |
ES (1) | ES2803578T3 (pt) |
HU (1) | HUE049104T2 (pt) |
LT (1) | LT3204494T (pt) |
MX (1) | MX2017004534A (pt) |
PE (1) | PE20171132A1 (pt) |
PH (1) | PH12017500627A1 (pt) |
PL (1) | PL3204494T3 (pt) |
PT (1) | PT3204494T (pt) |
SG (2) | SG10202010814RA (pt) |
SI (1) | SI3204494T1 (pt) |
UA (1) | UA125788C2 (pt) |
WO (1) | WO2016063291A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102219638B1 (ko) * | 2014-10-07 | 2021-02-23 | 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 | 엔테로바이러스 불활화 및 보강제 흡착 방법과 이로부터 수득되는 저용량 백신 조성물 |
ES2929274T3 (es) | 2016-05-10 | 2022-11-28 | Najit Tech Inc | Inactivación de patógenos y producción de vacunas inactivadas altamente inmunógenas utilizando un proceso de oxidación dual |
BR112019003419A2 (pt) * | 2016-08-26 | 2019-05-21 | Serum Institute Of India Private Limited | composição de vacina multivalente |
TWI711700B (zh) * | 2017-07-10 | 2020-12-01 | 印度商印度血清研究公司 | 使腸病毒去活化之改良方法、佐劑吸附及所獲得之劑量減少的疫苗組成物 |
EP3703741A1 (en) | 2017-11-03 | 2020-09-09 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
BR112020009960A2 (pt) | 2017-11-30 | 2020-11-10 | Takeda Vaccines, Inc. | método para a inativação de vírus zika e métodos relacionados |
SG11202007503WA (en) * | 2018-02-07 | 2020-09-29 | Bharat Biotech Int Ltd | A process for enterovirus purification and inactivation and vaccine compositions obtained thereof |
CN109550046B (zh) * | 2018-12-21 | 2020-08-25 | 北京民海生物科技有限公司 | 一种吸附无细胞百白破-脊髓灰质炎-b型流感嗜血杆菌联合疫苗及其制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL187935B1 (pl) * | 1996-07-02 | 2004-11-30 | Connaught Lab | Multiwalentna kompozycja immunogenna i jej zastosowanie |
MX2007002372A (es) * | 2004-08-27 | 2007-05-08 | Panacea Biotec Ltd | Vacuna para la poliomielitis inactivada derivada de la cepa sabin del virus de la polio. |
CN1647822A (zh) * | 2005-02-06 | 2005-08-03 | 北京生物制品研究所 | 脊髓灰质炎灭活疫苗及其制备方法 |
AU2007293672B2 (en) * | 2006-09-07 | 2013-06-27 | Glaxosmithkline Biologicals S.A. | Vaccine |
CN100540662C (zh) * | 2006-12-06 | 2009-09-16 | 云南沃森生物技术有限公司 | 一种混合床凝胶过滤层析技术用于病毒性疫苗纯化的方法 |
WO2010036226A1 (en) * | 2008-09-26 | 2010-04-01 | George Nelson | Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis |
BR112012014689B1 (pt) | 2009-12-16 | 2019-11-12 | Serum Institute Of India Private Limited | composição imunogênica |
ES2681698T3 (es) * | 2011-03-02 | 2018-09-14 | Glaxosmithkline Biologicals Sa | Vacunas de combinación con menores dosis de antígeno y/o adyuvante |
GB201105981D0 (en) * | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
KR102219638B1 (ko) | 2014-10-07 | 2021-02-23 | 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 | 엔테로바이러스 불활화 및 보강제 흡착 방법과 이로부터 수득되는 저용량 백신 조성물 |
-
2015
- 2015-10-06 KR KR1020177012227A patent/KR102219638B1/ko active IP Right Grant
- 2015-10-06 PE PE2017000562A patent/PE20171132A1/es unknown
- 2015-10-06 SI SI201531223T patent/SI3204494T1/sl unknown
- 2015-10-06 SG SG10202010814RA patent/SG10202010814RA/en unknown
- 2015-10-06 EP EP15831237.1A patent/EP3204494B1/en active Active
- 2015-10-06 SG SG11201702838SA patent/SG11201702838SA/en unknown
- 2015-10-06 PT PT158312371T patent/PT3204494T/pt unknown
- 2015-10-06 CN CN201580066368.0A patent/CN106999569B/zh active Active
- 2015-10-06 JP JP2017518817A patent/JP6755243B2/ja active Active
- 2015-10-06 EP EP20154738.7A patent/EP3663396A1/en active Pending
- 2015-10-06 UA UAA201704367A patent/UA125788C2/uk unknown
- 2015-10-06 AU AU2015334495A patent/AU2015334495B2/en active Active
- 2015-10-06 EA EA201700187A patent/EA201700187A1/ru unknown
- 2015-10-06 WO PCT/IN2015/000376 patent/WO2016063291A1/en active Application Filing
- 2015-10-06 BR BR112017007089A patent/BR112017007089A2/pt active Search and Examination
- 2015-10-06 HU HUE15831237A patent/HUE049104T2/hu unknown
- 2015-10-06 US US15/517,225 patent/US10485862B2/en active Active
- 2015-10-06 LT LTEP15831237.1T patent/LT3204494T/lt unknown
- 2015-10-06 MX MX2017004534A patent/MX2017004534A/es unknown
- 2015-10-06 CU CU2017000044A patent/CU24510B1/es unknown
- 2015-10-06 CN CN202110677385.5A patent/CN113368227A/zh active Pending
- 2015-10-06 CA CA2963897A patent/CA2963897C/en active Active
- 2015-10-06 DK DK15831237.1T patent/DK3204494T3/da active
- 2015-10-06 ES ES15831237T patent/ES2803578T3/es active Active
- 2015-10-06 PL PL15831237T patent/PL3204494T3/pl unknown
- 2015-10-06 KR KR1020217004836A patent/KR102510744B1/ko active IP Right Grant
-
2017
- 2017-04-05 PH PH12017500627A patent/PH12017500627A1/en unknown
-
2020
- 2020-06-25 CY CY20201100591T patent/CY1123078T1/el unknown
- 2020-08-25 JP JP2020142117A patent/JP7063957B2/ja active Active
-
2021
- 2021-11-18 AU AU2021269395A patent/AU2021269395B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017007089A2 (pt) | métodos melhorados para a inativação de enterovírus, adsorção de adjuvante e composições de vacina reduzidas por dose daí obtidas | |
DOP2016000107A (es) | PIRROLO[1,2-f][1,2,4]TRIAZINAS ÚTILES PARA TRATAR INFECCIONES POR EL VIRUS SINCITIAL RESPIRATORIO. | |
BR112016010716A8 (pt) | dose de reforço imunológico, baixa, de um inibidor de mtor, seu uso, e adjuvante de vacina | |
BR112017008959A2 (pt) | método para tratamento de uma doença. | |
PH12017500207A1 (en) | Indoles for use in influenza virus infection | |
NI201500062A (es) | Terapia adyuvante con inhibidores de quinasa de la familia tec | |
BR112017023374A2 (pt) | formulação de anticorpo anti-cgrp | |
ES2765949T8 (es) | Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer | |
BR112017004524A2 (pt) | pirrolopirimidinas para uso na infecção pelo vírus da gripe | |
BR112016025470A2 (pt) | ?hdl terapêutico? | |
TWD173829S (zh) | 緩衝裝置 | |
CO6551750A2 (es) | Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio | |
BR112017010440A2 (pt) | administração sublingual de riluzol | |
BR112017011556A2 (pt) | métodos para gerar um anticorpo sintético, prevenir ou tratar uma doença, tratar um sujeito de infecção por um patógeno e um sujeito com câncer, produto, molécula de ácido nucleico, e, composição. | |
BR112017003462A2 (pt) | coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino. | |
CL2015001562A1 (es) | Método para obtener una vacuna de mycoplasma. | |
BR112017008178A2 (pt) | ativador do canal de kcnq2-5 | |
UY36204A (es) | Derivados de insoindolina. | |
CL2019001200A1 (es) | Vacuna contra el parvovirus porcino y el virus del síndrome respiratorio reproductivo porcino y métodos de producción de esta. | |
MX2016016746A (es) | Composiciones de vacuna con adyuvante dual, preparacion y usos. | |
BR112017010423A2 (pt) | formulação sublingual de riluzol | |
TWD173830S (zh) | 緩衝裝置 | |
UA116697C2 (uk) | Композиція для запобігання зараженню видами роду mycoplasma | |
BR112017024401A2 (pt) | ?microrganismo do gênero escherichia que produz l-triptofano e método para produzir l-triptofano com o uso do mesmo? | |
BR112017013286A2 (pt) | composto de isoxazolina, e, uso de um composto de isoxazolina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] |